3550 W. Teco Avenue
Las Vegas, NV 89118
Authorized 200,000,000 - Outstanding 128,300,407 - Float 6,631,667
Effective December 1, 2017
The Company seeks to be an innovative technology and solution company that converts the cannabis plant into medicines, therapies and treatments
for a variety of ailments. The Company is developing and utilizing state of the art technologies in plant biology, cultivation and extraction techniques,
combined with biotechnology, and plans to produce consistent and measurable medical-grade cannabis, cannabis concentrates and cannabinoid therapies.
Although we believe that maximum shareholder value will ultimately be achieved through the development, production and marketing of certified cannabinoid
medicines, therapies and treatments, in order to generate cash flow and near term profitability, we intend to cultivate and dispense cannabis for medical
purposes in both Nevada and other states which permit such sales and in which we and our operating partners are able to obtain cultivation and dispensing licenses.
We seek to become a trusted producer of consistent and efficacious medicinal strains and products, combining both cannabinoids and terpenes, which we intend to market
in those states within the United States and in other countries where the sale of medical cannabis products are permitted. In addition, subject to obtaining
Food and Drug Administrative (FDA) certification, we intend to market our cannabinoid based drug discoveries on a world-wide basis.
GB Sciences partners with universities and contract research organizations (CROs), who bring both expertise and infrastructure at a reasonable cost
to our program. Our end goal is not to take these novel formulations to market ourselves, because we know our limitations.
Our goal is to be the perfect partner to those companies with greater resources and experience in the marketing and distribution of medications worldwide.